therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer

Molecular Diagnosis and Therapy

Volumn 20, Issue 2, 2016, Pages 191-198

  Syed, Yahiya Y ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; DIAGNOSTIC KIT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL PRACTICE; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; PYROSEQUENCING; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DIAGNOSTIC KIT; DNA MUTATIONAL ANALYSIS; GENETICS; LUNG NEOPLASMS; MUTATION; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DNA MUTATIONAL ANALYSIS; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REAGENT KITS, DIAGNOSTIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84958740825     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-016-0189-0     Document Type: Article

References (29)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.
2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci. 2004;101(36):13306–11.
4. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415–53.
5. Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011;22(7):1507–19.
6. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(Suppl 1):S24–31.
7. Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.
8. ® EGFR RGQ PCR Kit: instructions for use (Handbook). Manchester: QIAGEN; 2015.
9. QIAGEN. therascreen EGFR RGQ PCR Kit Handbook. Manchester: QIAGEN; 2012.
10. ® EGFR RGQ PCR kit: summary of safety and effectiveness data. 2013. http://www.fda.gov. Accessed 19 Nov 2015.
11. Vallée A, Le Loupp AG, Denis MG. Efficiency of the Therascreen RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas. Clin Chim Acta. 2014;429:8–11.
12. ® DSP DNA FFPE Tissue Kit Handbook. Hilden: QIAGEN; 2010.
13. QIAGEN. Lung cancer EGFR—labs. 2015. http://www.qiagen.com. Accessed 19 Nov 2015.
14. Wong AT, To RM, Wong CL, et al. Evaluation of 2 real-time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC. Diagn Mol Pathol. 2013;22(3):138–43.
15. Hinrichs JW, van Blokland WT, Moons MJ, et al. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice. Am J Clin Pathol. 2015;143(4):573–8.
16. Roma C, Esposito C, Rachiglio AM, et al. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int. 2013. doi:10.1155/2013/385087.
17. Lopez-Rios F, Angulo B, Gomez B, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol. 2013;66(5):381–5.
18. Kimura H, Ohira T, Uchida O, et al. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer. 2014;83(3):329–33.
19. Cushman-Vokoun AM, Crowley AM, Rapp SA, et al. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer. Am J Clin Pathol. 2013;140(1):7–19.
20. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.
21. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22.
22. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
23. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer. 2014;110(1):55–62.
24. US Food and Drug Administration. FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer [media release]. 13 July 2015. http://www.fda.gov.
25. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–8.
26. Westwood M, Joore M, Whiting P, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(32):1–166.
27. Hantson I, Dooms C, Verbeken E, et al. Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study. Transl Respir Med. 2014. doi:10.1186/s40247-014-0009-0.
28. Arriola E, Gomez RG, Diz P, et al. Observational retrospective study to describe the management of advanced epidermal growth factor receptor (EGFR) mutated (M+) non-small cell lung cancer (NSCLC) patients (pts) in Spain (NCT01795352) [abstract no. e19133]. J Clin Oncol. 2014;32.
29. Narita Y, Matsushima Y, Shiroiwa T, et al. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer. 2015;90(1):71–7.